hbv treatment controversies in 2009: a debate
DESCRIPTION
HBV Treatment Controversies in 2009: A Debate. Presented by The Johns Hopkins University School of Medicine Produced in collaboration with ViralEd LLC. Welcome and Introduction. Moderator: Albert Min MD Discussants: Mark Sulkowski MD Douglas Dieterich MD. - PowerPoint PPT PresentationTRANSCRIPT
HBV Treatment Controversies in 2009:
A DebatePresented by The Johns Hopkins University School of Medicine
Produced in collaboration with ViralEd LLC
Welcome and Introduction
Moderator: Albert Min MD
Discussants: Mark Sulkowski MD
Douglas Dieterich MD
Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement:The Johns Hopkins University School of Medicine designates this
educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the
extent of their participation in the activity.
To obtain CME credit, go to the heading “Instructions forObtaining Continuing Medical Education Credit” on the home
page of this program and click on the “CME Post Test andEvaluation” link.
Program Objectives
At the conclusion of this activity the participant should be able to:
1. Summarize, discuss with colleagues, and apply clinically the most recent and relevant data on the diagnosis, management and treatment of CHB including the use of new diagnostic and monitoring tools and recently approved therapies;
2. Assess CHB patients and make an appropriate clinical decision regarding the role of and need for liver biopsy;
3. Review patient case scenarios and be able to outline and discuss the factors to consider when deciding on when to start CHB therapy;
4. Be aware of and knowledgeable about the risks and benefits of various CHB therapies currently available;
5. Assess and explain the potential role of combination therapy in treatment-naïve and treatment-experienced patients; and
6. Evaluate the potential role for HBV resistance testing and the potential for resistance associated with various CHB treatment strategies in the context of clinical case scenarios.
Course Directors
Douglas T. Dieterich, MDProfessor of Medicine and Director of CME,
Department of Medicine, Director of Outpatient Hepatology,
Division of Liver Diseases,
Mount Sinai School of Medicine
Mark Sulkowski, MDAssociate Professor of Medicine and Medical Director,
Viral Hepatitis Center,
Johns Hopkins University School of Medicine
Faculty
Nezam H. Afdhal, MDBeth Israel DeaconnessMedical CenterHarvard Medical School
Robert S. Brown, Jr., MD, MPHColumbia UniversityMedical Center
Steven L. Flamm, MDNorthwestern FeinbergSchool of Medicine
Ira Jacobson, MDNewYork-Presbyterian HospitalWeill Cornell Medical College
Paul Kwo, MDIndiana UniversitySchool of Medicine
Paul Martin, MD, FACPUniversity of MiamiMiller School of Medicine
Fred Poordad, MDCedars-Sinai Medical CenterDavid GeffenSchool of Medicine at UCLA
Tram T. Tran, MDCedars Sinai Medical CenterDavid Geffen School of Medicine at UCLA
Naoky Tsai, MDJohn A. BurnsSchool of MedicineUniversity of Hawaii
Disclosures
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the
policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of
any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturers of any commercial products discussed in an educational presentation. The disclosures of the faculty for this program can be found in your handout materials and are presented in the following slides:
DisclosuresMark Sulkowski, MD
– Sources of Funding for Research: Roche, Schering-Plough, Vertex, Human Genome Sciences, Boehringer-Ingelheim, Merck, Idenix, Valeant, Mederax, Tibotec, Gilead Sciences.
– Consultant: Roche, Schering, Vertex, HGS, Boehringer-Ingelheim, Tibotec, Bristol Myers Squibb
Douglas Dieterich, MD– Grant Research: Boehringer-Ingelheim, Gilead Sciences
– Consulting Agreements: Roche, Tibotec, BMS, Gilead Sciences, Boehringer-Ingelheim
– Speakers' Bureau/Honorarium Agreements: Roche, Tibotec, BMS, Gilead Sciences, Boehringer-Ingelheim, GlaxoSmithKline
Albert Min, MD– Grant Research/Consultant/Honorarium/Speaker Bureau:
Bristol Myers Squibb, Gilead Sciences
This presentation includes information on studies and data presented off-label uses of entecavir, tenofovir, adefovir, interferon, lamivudine
The Johns Hopkins University School of Medicine
takes responsibility for the content, quality, and
scientific integrity of this CME activity.